GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.
Hospital Universitario Virgen del Rocío/Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla, Sevilla, Spain.
R
R
Parody
Hospital Universitario de Salamanca, Salamanca, Spain.
L
L
López-Corral
Hospital Universitario de Salamanca, Salamanca, Spain.
O
O
Lopez-Godino
Hospital Clinic de Barcelona, Barcelona, Spain.
C
C
Martinez
Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Institute, Universidad Autónoma de Barcelona, Barcelona, Spain.
R
R
Martino
Hospital Clínico de Valencia, Valencia, Spain.
C
C
Solano
Hospital Vall d'Hebron, Barcelona, Spain.
P
P
Barba
Hospital Universitario de Salamanca, Salamanca, Spain.
D
D
Caballero
Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Institute, Universidad Autónoma de Barcelona, Barcelona, Spain.
I
I
García-Cadenas
Hospital Clínico de Valencia, Valencia, Spain.
J L
JL
Piñana
Hospital Universitario Virgen del Rocío/Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla, Sevilla, Spain.
F J
FJ
Marquez-Malaver
Hospital Universitario de Salamanca, Salamanca, Spain.
L
L
Vazquez
Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Institute, Universidad Autónoma de Barcelona, Barcelona, Spain.
A
A
Esquirol
Hospital Clínico de Valencia, Valencia, Spain.
J C H
JC
Boluda
Hospital Universitario de Salamanca, Salamanca, Spain.
F
F
Sanchez-Guijo
Hospital Universitario Virgen del Rocío/Virgen Macarena, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla, Sevilla, Spain.
J A
JA
Pérez-Simon
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000627:therapeutic use; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus